HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
Public ClinicalTrials.gov record NCT05902494. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Retrospective Chart Review of Real-world Treatment Outcomes in Patients With Locally Advanced Unresectable or Metastatic Urothelial Cancer Based on HER2 Expression
Study identification
- NCT ID
- NCT05902494
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Enrollment
- 389 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2023
- Primary completion
- Jun 17, 2025
- Completion
- Jun 17, 2025
- Last update posted
- Jul 19, 2025
2023 – 2025
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| University of California Irvine | Orange | California | 92868 | — |
| Stanford Cancer Institute - School of Medicine | Palo Alto | California | 94394 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| University of California Los Angeles | Santa Monica | California | 90404 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| ICAHN School of Medicine at Mount Sinai, | New York | New York | 10029 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Duke Cancer Institute - School of Medicine | Durham | North Carolina | 27710 | — |
| Avera Cancer Institute Center | Sioux Falls | South Dakota | 57104 | — |
| Vanderbilt - Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05902494, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05902494 live on ClinicalTrials.gov.